Jun 30, 2022–RhoVac provides a status update and investigates a potentially accelerated repayment of the convertible loan (regulatory)May 29, 2022–RhoVac’s phase IIb study in prostate cancer , BRaVac, failed to meet its primary endpoint (regulatory)May 18, 2022–Pre-clinical findings support the potential use of RhoVac’s drug candidate, onilcamotide, across several cancers (regulatory)
